Lung disorders

aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung

Retrieved on: 
Thursday, July 29, 2021
Protein biosynthesis, Autoimmune diseases, Lung disorders, Branches of biology, Histidine—tRNA ligase, Transfer RNA, Biology, Aminoacyl tRNA synthetase, Sarcoidosis, Chemistry, aTyr Pharma, Xiang-Lei Yang

11,072,787 entitled, Histidyl-tRNA synthetase-FC conjugates, covers the use of the companys lead therapeutic candidate, ATYR1923, for reducing inflammatory response in the lung.

Key Points: 
  • 11,072,787 entitled, Histidyl-tRNA synthetase-FC conjugates, covers the use of the companys lead therapeutic candidate, ATYR1923, for reducing inflammatory response in the lung.
  • ATYR1923 is a Fc fusion protein based on the N terminal fragment of histidyl-tRNA synthetase that is currently in clinical development for the treatment of pulmonary sarcoidosis and is being evaluated in other inflammatory lung diseases.
  • These patents encompassed important new therapeutic modalities which underpin the broad pipeline of novel therapeutics in active development at the company.
  • aTyr is developing ATYR1923 as a potential therapeutic for patients with inflammatory lung diseases.

Idiopathic Pulmonary Fibrosis (IPF) Clinical Landscape Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Pharmaceutical, Health, Clinical trials, Medical devices, Idiopathic pulmonary fibrosis, Lung disorders, Boehringer Ingelheim, Pulmonary fibrosis, IPF, Health, Orphan drugs, Organ systems, Monoclonal antibodies, Pneumonia, Fresolimumab

The "Market Spotlight: Idiopathic pulmonary fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Idiopathic pulmonary fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The majority of industry-sponsored drugs in active clinical development for IPF are in Phase I.
  • Roche leads the industry sponsors with the highest overall number of clinical trials for IPF, closely followed by Boehringer Ingelheim.

Idiopathic Pulmonary Fibrosis (IPF) Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Managed care, Health, Lung disorders, Idiopathic pulmonary fibrosis, Pulmonary fibrosis, IPF, Clinical medicine, Medical specialties

The "Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Idiopathic Pulmonary Fibrosis (IPF)- Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Idiopathic Pulmonary Fibrosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
  • The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries.
  • The epidemiology data for Idiopathic Pulmonary Fibrosis are studied through all possible division to give a better understanding about the Disease scenario in 7MM.

Corsair Pharma, Inc. to Host Key Opinion Leader Meeting on Pulmonary Arterial Hypertension

Retrieved on: 
Thursday, June 24, 2021
Anatomy, Lung disorders, Medical emergencies, Hypertension, Pulmonary hypertension, Pulmonary artery, Pulmonology, Pulmonary fibrosis, Pulmonary embolism, Embolism, Lung, Jason X.-J. Yuan

Dr. Channick is Professor of Medicine and Saul Brandman Endowed Chair of Pulmonary Arterial Hypertension at David Geffen School of Medicine at UCLA.

Key Points: 
  • Dr. Channick is Professor of Medicine and Saul Brandman Endowed Chair of Pulmonary Arterial Hypertension at David Geffen School of Medicine at UCLA.
  • Dr. Channick has published over 200 original articles, chapters and reviews focused on all aspects of pulmonary hypertension and pulmonary embolism.
  • Next, Dr. Feldman moved to Phoenix and joined Arizona Pulmonary Specialists where he started a pulmonary hypertension and advanced lung disease program.
  • He has developed leading educational websites for pulmonary hypertension www.pulmonaryhypertensionRN.com and pulmonary fibrosis www.pulmonaryfibrosisMD.com , and founded www.PFAdvisors.com .

Simulations Plus Releases IPFsym version 1A, State-of-the-Art Quantitative Systems Pharmacology (QSP) Software for Idiopathic Pulmonary Fibrosis (IPF)

Retrieved on: 
Thursday, June 17, 2021
Data management, Health, Technology, Software, Pharmaceutical, Biotechnology, Medicine, Health sciences, Clinical medicine, Lung disorders, Simulation software, Simulations Plus, Idiopathic pulmonary fibrosis, Pulmonary fibrosis, Simulation, Quantitative systems pharmacology, IPF, Fibrosis

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has released IPFsym version 1A, quantitative systems pharmacology modeling software to support the development of treatments for idiopathic pulmonary fibrosis.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has released IPFsym version 1A, quantitative systems pharmacology modeling software to support the development of treatments for idiopathic pulmonary fibrosis.
  • IPF is the most common type of pulmonary fibrosis, a disease that causes scarring (fibrosis) of the lungs.
  • The combination of IPFsym and our scientific consulting expertise is positioned to support our clients in this important field.
  • Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions.

Pulmonary Fibrosis Foundation Launches New Website

Retrieved on: 
Wednesday, June 16, 2021
Lung disorders, Clinical medicine, Pulmonary rehabilitation, Respiratory therapy, Pulmonary fibrosis, Anatomy, Pulmonology

CHICAGO, June 16, 2021 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis education and advocacy organization, has launched a new website, pulmonaryfibrosis.org , for the more than 200,000 Americans impacted by pulmonary fibrosis (PF), a group of debilitating lung diseases.

Key Points: 
  • CHICAGO, June 16, 2021 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis education and advocacy organization, has launched a new website, pulmonaryfibrosis.org , for the more than 200,000 Americans impacted by pulmonary fibrosis (PF), a group of debilitating lung diseases.
  • The new website was funded through a grant from Three Lakes Foundation.
  • Patient resources on the new site include disease education videos and webinars, fact sheets on the types of pulmonary fibrosis, and a pulmonary rehabilitation toolkit.
  • The Pulmonary Fibrosis Foundation mobilizes people and resources to provide access to high-quality care and leads research for a cure so people with pulmonary fibrosis will live longer, healthier lives.

Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline)

Retrieved on: 
Wednesday, June 16, 2021
Acid-fast bacilli, Mycobacterium abscessus, Health, Medical specialties, Microbiology, Lung disorders, Nontuberculous mycobacteria

Pulmonary infections caused by MABc, an orphan disease with no FDA-approved antibiotic therapies, affects approximately 11,500 patients in the U.S.

Key Points: 
  • Pulmonary infections caused by MABc, an orphan disease with no FDA-approved antibiotic therapies, affects approximately 11,500 patients in the U.S.
  • Patients with pulmonary disease caused by M. abscessus have a myriad of symptoms including severe fatigue, fever, cough and shortness of breath.
  • The Phase 2b study is a placebo-controlled, randomized monotherapy study of M. abscessus pulmonary disease in patients in the early treatment phase who are not receiving other treatments.
  • Due to the small numbers of patients with this rare disease, Paratek expects the study will take about two years to complete enrollment.

MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases

Retrieved on: 
Thursday, June 10, 2021
MannKind Corporation, Thousand Oaks, California, Lung disorders, Pulmonary fibrosis, Idiopathic pulmonary fibrosis

TGF- is also implicated in lung fibrotic diseases and ALK-5 has been validated as a potential target for idiopathic pulmonary fibrosis, said Thomas Hofmann, M.D., Ph.D., Chief Scientific Officer of MannKind Corporation.

Key Points: 
  • TGF- is also implicated in lung fibrotic diseases and ALK-5 has been validated as a potential target for idiopathic pulmonary fibrosis, said Thomas Hofmann, M.D., Ph.D., Chief Scientific Officer of MannKind Corporation.
  • This collaboration with MannKind gives Thirona the opportunity to potentially expand the development of FBM5712 into fibrotic lung diseases with a new formulation, said Dr. Gordon Foulkes, Thirona Bios Founder and Chief Executive Officer.
  • Thirona Bio is focused on the development of drugs for fibrotic diseases.
  • MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases.

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

Retrieved on: 
Thursday, June 10, 2021
Branches of biology, Medical specialties, Anatomy, Cystic fibrosis, Lung disorders, Channelopathies, Respiratory therapy, Mucus, Nebulizer, Denufosol

Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.

Key Points: 
  • Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • Since its inception in 2014, Nuance Pharma has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain and iron deficiency anemia.

Optime Care’s Patient-First Strategy Helps Physicians Optimize Care for Rare and Orphan Disease Patients with Pulmonary Issues During COVID-19 Pandemic

Retrieved on: 
Wednesday, June 9, 2021
Technology, Nursing, Infectious diseases, Hospitals, Genetics, Practice Management, Managed care, Pharmaceutical, Health, Data management, Anatomy, Medical specialties, Organs anatomy), Hepatology, Acute-phase proteins, Lung disorders, Alcohol and health, Alpha-1 antitrypsin, Alpha 1, Liver disease

This is especially important for patients with Alpha-1 Antitrypsin Deficiency (Alpha-1), a genetic condition that may result in serious lung disease in adults and/or liver disease at any age.

Key Points: 
  • This is especially important for patients with Alpha-1 Antitrypsin Deficiency (Alpha-1), a genetic condition that may result in serious lung disease in adults and/or liver disease at any age.
  • Optime Cares patient-first approach offers patients a proactive, process-driven telehealth program which mitigates the transmission of infection, such as coronavirus, for these vulnerable individuals.
  • This focus addresses all variables around collecting data, while maintaining frequent communication with patients and their families to ensure compliance and positive outcomes.
  • Listen to Optime Cares Rare Voices podcast episode with Dr. Miskoff here .